Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00649389 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,500
- Enrollment target
NCT00649389 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 2,500 participants.
The verdict
NCT00649389, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,500 participants
- Enrollment target
Study Summary
To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
Interventions
- DRUG Amlodipine
- DRUG Olmesartan medoxomil
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00649389
The ClinicalTrials.gov registry entry for NCT00649389 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Amlodipine is the first listed.
NCT00649389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00649389 about?
NCT00649389 is a clinical study titled "Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension". To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
What is the current status of trial NCT00649389?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,500 participants. The study started on 2008-05. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00649389?
The interventions under investigation include: Amlodipine (DRUG), Olmesartan medoxomil (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00649389?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.